Qiagen (QGEN) said Tuesday the German Federal Patent Court reaffirmed the validity of a patent protecting its QuantiFeron technology.
The court's decision upholds Qiagen's intellectual property rights involving the German part of a European patent, which protects its technology in detecting latent tuberculosis, the company said late Tuesday.
"Patents covering these innovations have been issued to Qiagen in several other countries, and form part of a group of more than 120 patents currently issued for QuantiFERON," the company added.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。